Merck, Inc.
🇵🇭Philippines
Lipid Efficacy/Tolerability Study (0524A-020)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2015-07-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1620
- Registration Number
- NCT00269204
Lipid Efficacy Study (0524B-022)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1400
- Registration Number
- NCT00269217
The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-12-19
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 210
- Registration Number
- NCT00266799
Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2005-12-19
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 35
- Registration Number
- NCT00266812
Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)
- First Posted Date
- 2005-12-14
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1428
- Registration Number
- NCT00265395
Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 680
- Registration Number
- NCT00260039
V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-11-24
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 403
- Registration Number
- NCT00258154
Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 121
- Registration Number
- NCT00255008
Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 593
- Registration Number
- NCT00254982
Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 146
- Registration Number
- NCT00255034
© Copyright 2024. All Rights Reserved by MedPath